Blueberry Therapeutics will use the proceeds from the $12.8m China Medical System-backed round to advance its skin and nail infection treatments.

UK-based nanomedicine developer Blueberry Therapeutics has closed a £10m ($12.8m) series B round that included China Medical Venture Investment (HK), an investment vehicle for pharmaceutical company China Medical System Holdings (CMS). The round also featured A&B Holdings, an investment and development vehicle led by CMS chairman Lam Kong. Blueberry is working on nanotechnology-formulated drugs to…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.